Views & Analysis | Perspectives on pharma industry issues

R&D

Alzheimer's research is moving toward more selective targets

As we mark World Alzheimer’s Day, it is worth reflecting on the progress made in recent years.

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access

From first approval to lasting value: What sets successful e...

Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.

Market Access

drug pricing in the UK, pills overlain on map

Request to look further into NICE non-submissions in the fut...

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.

R&D

Changing Faces: Board of Director and Advisory Board hires, ...

Boardrooms, Advisory Boards, and governance teams saw plenty of activity in August.

Articles

Perspectives on CME: part 5 – the future of CME

In the final part of our interview series with Lawrence Sherman, he explores the future of CME and how CME activities need to be better coordinated globally. This series has so far covered the value of CME, the role of the patient and pharma in CME and how technology has shaped education....

Articles

Individualised approaches to medicine

Mark Frohlich of Dendreon speaks with pharmaphorum about personalised medicine and the potential of immunotherapies. Personalised medicine has attracted much media attention of late. Immunotherapy harnesses a patient’s own immune...

Articles

What’s going on in the vaccine space right now?

pharmaphorum speaks to Nikolai Petrovsky of Vaxine on the latest challenges to face the vaccine space and where he sees vaccine development formulation with adjuvants heading. What challenges are currently facing the vaccine space? What therapeutic areas hold the most promise for vaccines? And where…

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Sales & Marketing

Wooden pawns representing number of employees

Headcount is not a growth strategy

Deciding when, where, and how quickly to add headcount is rarely straightforward.

Digital

Pharma brands face golden opportunity to extend supply chain...

People are ready for technology that verifies authenticity and provides helpful information directly from the medicinal product itself.

Digital

Changing Faces: Digital and supplier hires, August 2026

Digital health, clinical technology, contract services, and life sciences suppliers all saw notable leadership changes last month.

Market Access

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access